Video
6 Oct 2022

Bringing Innovative Therapies to Market Through an Enhanced Integrated Approach

In Dec 2021, Thermo Fisher completed the acquisition of PPD, Inc, a leading global provider of clinical research services to the biopharma and biotech industry. With the addition of PPD, Thermo Fisher will offer a comprehensive suite of world-class services across the clinical development spectrum – from scientific discovery, to accessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of drug product.

Today a panel of executives from Thermo Fisher will discuss how the addition of PPD’s leading clinical research services differentiates Thermo Fisher and advances our work in bringing life-changing therapies to market, benefiting patients around the world.

Today’s learning lounge will provide insight into how a patient centric mindset influences:

  • drug development and manufacturing decisions
  • clinical trial recruitment, retention and trial management
  • end-to-end processes, from early drug development to the patient



  • Click here to register


    Content provided by our supplier

    Thermo Fisher Scientific Inc.

    • US
    • 2015
      On CPHI since
    • 5000+
      Employees
    Company types
    CMO/CDMO
    Primary activities
    Clinical Research
    Contract Manufacturer
    Contract Research Organisation
    Packaging & drug delivery
    Supply Chain

    Other Content from Thermo Fisher Scientific Inc. (55)

    • News New CPHI report looks at CDMO outsourcing and partner selection

      In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies in use

    • Brochure Made with proof & purpose

      Your molecule has the potentialto change lives and shape thefuture. That’s why you need apartner you can trust.
    • News Viral vector demand to flourish on wave of imminent approvals, CPHI Worldwide audience told

      Expected increase in approvals for gene therapies, gene-modified cell therapies and recombinant vector vaccines will also increase pressure on manufacturers to build new capacity
    • Brochure Fact sheet: Biologics Quick to Clinic™

      Thermo Fisher Scientific is your global partner of choice for an integrated solution to streamline your drug development program. We understand the complex journey ahead and are experienced in working with new and emerging clients. In 2020, 69 percent of our new business in product development was with new and emerging clients – 278 drug development projects in 2020 alone, including 139 Phase I projects, 57 Phase II projects, and 82 Phase III projects. As an industry-leading partner with a proven track record, we have outsourced 109 NDA approvals in the last decade—that’s more than three times the number of the next-ranking CDMO.
    • News Increasing demand for outsourced manufacturing due to changing Chinese market conditions, CPHI Worldwide conference told

      Rise of innovative companies with high-risk portfolios will necessitate need for CDMOs, says Thermo Fisher senior executive

    • Brochure Brochure: Quick to Care™ Program

      Quick to Clinic™ is an integrated early development offering designed for biotech companies looking for a dependable solution to scale up recombinant antibodies from discovery to first-in-human (FIH) trials.
    • News CPHI Webinar: mRNA vaccines, Trends, Technologies and Supply Chain

      The COVID-19 pandemic has meant scientists, together with pharmaceutical companies, have had to reinvent how to bring vaccines to market faster without impacting product quality, safety, or efficacy, according to experts speaking at a recent CPHI webinar.
    • Brochure From Molecule to Medicine

      One integrated partner for every step of your drug development journey.
    • News Thermo Fisher takes on operational responsibility for new Swiss biologics manufacturing site

      The 1.5 million-sq. ft Switzerland-based facility is part of the company's strategic partnership with CSL Limited
    • Brochure Growing your biopharma

      Ten questions you're likely to face from investors and how to respond to them.
    • Sponsored Content Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California

      Responding to critical market capacity constraints, Thermo Fisher announces the official opening of new 67,000 sqft cGMP plasmid DNA manufacturing facility in Carlsbad, CA. This site expands clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies in addition to capabilities to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
    • Brochure Five ways to get to IND_IMPD faster

      The road to IND/IMPD isn’t always easy. Balancing speed, risk, and future needs is a challenge. So how do you get to IND/IMPD faster without sacrificing quality and future commercialization goals? Our experts have shared a few things to consider when thinking about accelerating and optimizing your early development process.
    • News Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland

      Thermo Fisher Scientific Inc., the world leader in serving science,  announced that it has assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL Limited announced last year. The Lengnau site will become part of Thermo Fisher's global biologics manufacturing network, and approximately 200 employees will join Thermo Fis
    • Brochure Pharma Services' scientific innovation and investments

      Simplifying and accelerating your journey to market by providing the end-to-end solution you need.
    • News Thermo Fisher to build facility in Nashville for production of single-use technologies products

      Investment will further expand CDMO's global network of SUT facilities to boost reliable supply of critical materials used to produce new biologics and vaccines
    • Brochure Drug repurposing trends and strategic approaches for shortening timelines

      As the complexity of drug development increases, so does the industry’s focus on strategies and solutions that can help bring advanced products to market as quickly as possible. Lowering the cost of R&D is also a key factor, as new chemical entities and de novo drugs in clinical phases face high attrition rates, with companies losing significant investments in nonviable candidates. One approach to avoiding this fate is drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications. Understanding drug repurposing, how it can significantly reduce your time to market, and the important role established and knowledgeable CDMOs can play in this journey is critical to finding success with this emerging strategy.
    • News Thermo Fisher Scientific and AstraZeneca sign NGS-based CDx co-development agreement

      Companies say earlier collaboration may speed development and introduction of targeted precision medicine therapies for patients.
    • Brochure Setting a strong foundation for your oral solid dose product to support late-stage development

      Drug sponsors face significant pressure to reduce the time required to move a new molecule through Phase I and into Phase II trials. If all goes well, identifying the quickest scale-up path for supplying efficacy trials and commercial demands is next. But at early stage, sponsors need to keep the formulation as simple as possible. This means identifying the desired critical quality attributes of a formulation and selecting only those must-have requirements that align closest to the objectives of each clinical trial stage.
    • News Thermo Fisher pledges to reach carbon neutrality by 2050

      Accelerated efforts align with the Paris Agreement and Race To Zero to combat climate change
    • Brochure Navigating the Adoption of Continuous Pharma Manufacturing Amid Unprecedented Global Challenges

      In addition to the devastating impact the COVID-19 global pandemic has had on public health, the economy, and the overall quality of our day-to-day lives, it has also exposed significant risks in today’s pharmaceutical supply chain. Improvements in speed to market and quality assurance, among other factors, need to be made to ensure not only the timely delivery of safe and efficacious drugs but also the stability necessary to manage future risks and disruptions.
    • News Thermo Fisher supports gene developers with new AAV manufacturing solutions

      A new media panel, gene kit and advanced resins help reduce manufacturing costs and increase the viability of gene therapies
    • Brochure Impact of a Pandemic Outbreak on Vaccine Development Approach

      Over the past decade, outbreaks of H1N1 influenza, Sars-Cov, Ebola, and MERS have triggered several discussions about traditional vaccine development methods1. For example, new platform technologies, such as the use of messenger RNA (mRNA) vehiculated through lipid nanoparticles, have been introduced, stimulating scientific discussions. With the spread of SARS-CoV-2 intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring these life-saving drugs to market faster without impacting product quality, safety, or efficacy.
    • News Thermo Fisher buys Novasep viral vector manufacturing business

      Expanded global capacity addresses growing demand for cell and gene therapy
    • Whitepaper The Future of Outsourcing – Strategies for Partner Selection

      How can innovators select the right outsourcing partners to work with their in-house teams? This report will examine current outsourcing strategies, and assess which approaches work best for specific products, and for particular development/manufacturing pathways. In a market where CDMOs and development partners are in incredibly high demand, this report considers current market trends, the changing development goals for biotech and pharma, and how outsourcing strategies are now evolving. Calling on market experts from across the outsourcing sector, this report will collate expertise for a comprehensive overview of the manufacturing, outsourcing, and partnering landscape.
    • News Thermo Fisher boosts clinical supply chain and distribution services in Europe

      Two new facilities in Germany will provide clinical supply and cold chain services to support growing demand
    • Whitepaper mRNA vaccine development: Key insights for planning, workflow, and supply chain success

      In this report, we will review key insights derived from the development of mRNA-based COVID-19 vaccines and how they can be applied to accelerate progress in the manufacture of mRNA vaccines and therapeutics moving forward, focusing on the following: The unique attributes of mRNA vaccine development The planning paradigm shift to address major process challenges and streamline workflow Global supply chain implications and the investments and innovations needed to manage them.
    • News Thermo Fisher releases new CE-marked combo testing kit

      The single PCR-based diagnostic kit can detect and differentiate between SARS-CoV-2, influenza (flu) A/B, and RSV
    • Whitepaper Getting to first-in-human clinical trials_ A make-or-break milestone for small biopharmas

      “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market quicker than ever before. The incentive of securing market share with first-to-market offerings is felt by all industry players. Pressure mounts from here for small companies, which often must meet certain milestones before receiving funding from investors. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for cash-strapped companies whose hopes for success hinge upon just one or two molecules.
    • News Thermo Fisher Scientific Opens New Bioprocessing Collaboration Center in St. Louis

      Thermo Fisher Scientific Inc., the world leader in serving science, announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri.
    • Whitepaper Strategic CDMO partnerships: Leveraging infrastructure investments and innovation to accelerate biologics development

      Rising to the challenges of biologics development in this period of disruptive change requires an appreciation for the science, technology, and market forces driving the transformation and a willingness to adopt strategies that align with these changes. For most pharmaceutical and biotech companies, this means identifying trusted partners who can provide access to innovative technologies and methodologies, sufficient manufacturing capacity for growing biologics demand, deep expertise in navigating regulatory channels, and the operational efficiencies needed to accelerate speed to market. This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
    • News INOVIO signs up Thermo Fisher to support COVID-19 vaccine production

      The CDMO will support INOVIO's plans to have 100 million doses of COVID-19 vaccine candidate INO-4800 manufactured in 2021.
    • News Thermo Fisher seals US government deal to supply VTM tubes for COVID-19 testing

      CDMO aims to ramp up production to 8 million tubes per week via $40 million Lenexa site expansion
    • Video Technology Transfers: Best practices for Optimizing Success and Mitigating Risk

      When working with the right partner and network, transferring production between sites allows companies to reap a variety of strategic advantages. Timeline and cost efficiencies can be gained when a trusted CDMO can take a product from development to commercial launch.

      They can safeguard supply by producing at more than one site, and improve distribution by moving production closer to a critical market. Program costs and risk can be reduced by moving production to sites that are better qualified or better positioned to meet the needs of regulators. But this is not without challenges.

      Learn how Thermo Fisher Scientific: Uses a network of technical experts and digital innovations for project management to overcome key industry challenges related to tech transfers Customizes the approach for the process transfer, stylizing it specific to our customers Takes the lead in effectively managing projects through the most complex regulatory strategies by executing consistent, quality manufacturing Applies an optimized governance model and an integrated network approach to de-risk and simplify the transition of the program to commercial stage In this learning lounge, we will showcase what differentiates Thermo Fisher Scientific in the technology transfer market and how the power of our network consistently delivers speed through efficiency.


      Click here to register

    • News Thermo Fisher to more than double viral vector capacity through Plainsville addition

      CDMO will build a $180 million development and manufacturing facility to support increasing demand for cell and gene therapies and vaccines
    • Video China: Opportunities & High Growth Potential for Global and Domestic Pharma

      Originally broadcast as part of the CPHI Worldwide 2021 digital content agenda, this session will provide an overview of the opportunities and challenges for growth in the world's second largest pharma market. Speakers from Thermo FIsher and Informa Pharma Intelligence will explore some of the consistent drivers for investment and innovation trends through the views of thought leaders in China's pharma industry. Discussion points include: Market Dynamics & Industry Trends Opportunities in Drug Development and Clinical Research Best practices in supporting global Pharma companies to access China How Pharma companies in China can leverage the experience of the Global Market
    • News Thermo Fisher to invest more than $475 million this year on capacity and capability expansion

      Thermo Fisher Scientific will invest more than USD475 million in 2020 in new capabilities and capacity to meet increasing demand for biologics, cell and gene therapies and drug products, the contract development and manufacturing organisation said Monday.
    • Video Building Viral Vector Capacity and Capabilities to Realise the Promise of Gene Therapies

      This session was originally broadcast live on 1 November as part of the CPHI Worldwide digital content programme, and is now available to view on-demand. Continuing advances in cell and gene therapy are transforming how biopharma companies treat and potentially cure certain diseases. This session will touch upon some of the opportunities, challenges, and implications for stakeholders in this fast-evolving field and provide a guide on how to Build Viral Vector Capacity and Capabilities to Realise the Promise of Gene Therapies. Discussion points include: Challenges and opportunities of bringing viral vector products to market Importance of building capacity and capabilities to meet future needs Addressing scalability challenges
    • News Thermo Fisher Scientific to acquire Qiagen

      Thermo Fisher Scientific said Tuesday it has agreed to buy Dutch molecular testing and diagnostics specialist Qiagen for €39 per share in cash, valuing the overall transaction at around USD 11.5 billion.
    • Video Developments and Opportunities in Continuous Manufacturing

      This session was originally broadcast as part of the CPHI Worldwide digital content programme. Continuous Manufacturing is a premier event for modernizing pharmaceutical manufacturing and accelerating commercial success. Even though the move towards the use of these techniques has been slow, more and more facilities are choosing continuous manufacturing processes when introducing a new product. This session will explore: Level of adoption of continuous pharmaceutical manufacturing: Drivers and challenges The current state of continuous manufacturing of API, FDF, and biologics: Overview and key differences Importance of the catalytic role of National Regulatory Agencies and pharmacopoeias for increased continuous processing of the pharmaceutical products
    • News New advanced LC system delivers productivity, precision and compliance

      The Vanquish Core HPLC System maximizes the delivery of precise results with simple, seamless method transfer.
    • Video The Lasting Impact of COVID-19 on Drug Development

      A disrupter event to many businesses and industries worldwide, what lasting impacts will be felt and what can pharma learn from the COVID-19 pandemic in terms of the acceleration of drug development and repurposing in the future; the broader impact on how trials are conducted, and the impact of virtual clinical trials for clinical supplies business. Discussion Points Fast-tracking R&D Emergency use approvals Drug Repurposing Diversifying Clinical trials This session was originally broadcast live as part of CPHI North America 2021
    • News Thermo launches next-generation, compressor-free plate sealer

      Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.
    • Video Navigating Decision Points to Fast-Track Commercialisation

      This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Understanding the risks, requirements and challenges of bringing clinical products through validation and to the market are vital for the success of your large molecule project. Whether you are experiencing resource constraints or struggling with the right level of technical expertise, navigating key decision points within early development can pose a lot of challenges. Optimizing your decision making can save time and costs by avoiding rework and delays. During this webinar, learn more about: Strategies for formulation development vs. process development How to change presentation/dose and the appropriate timing Selecting the right scale at each phase and for commercial launch Limiting waste throughout your project Readiness for validation Executing PPQ Case studies: Small molecule lyo – large scale Large molecule liquid – small scale
    • News Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

      Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.
    • Video Manufacturing Innovation: The Case for Continuous Manufacturing

      This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Technologies with the potential to accelerate product development, reduce manufacturing costs and facilitate speed to market will be one of the leading change drivers for pharma manufacturing processes in coming years. Continuous Manufacturing has been widely touted as an approach for creating efficiencies in pharma manufacturing and accelerating commercial success. While industry adoption has been slow, more and more facilities are choosing continuous manufacturing processes when introducing a new product. What are some of the latest breakthrough technologies being implemented by pharmaceutical manufacturers? Guidance for Industry: Quality and regulatory Considerations for Continuous Manufacturing Batch vs Continuous Manufacturing Critical success factors and common pitfalls Hybrid-type manufacturing systems? Continuous manufacturing – a technology suited to new products and new facilities rather than existing ones?
    • News Automation-compatible prepared culture media plate technology

      Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.
    • Video Thermo Fisher Pharma Services: COVID-19 Mobilization

      We're working arm-in-arm with industry innovators, government agencies and academic institutions to provide scale, flexibility and expertise in the battle against COVID-19.
    • News New campaign from Thermo Fisher Scientific puts a face on pharma manufacturing

      First Pharma Services brand campaign from Madras celebrates the unsung heroes who get life-saving drugs to market.
    • Webinar Continuous Manufacturing- What's Driving Adoption?

      CDMO’s accelerating adoption Reshoring: CM can help when competing with Asian producers on price. Government investment during Covid to protect against supply chain issues & increased focus on critical drugs supply New guidance based on GMP - ICH Q13 will likely see smaller companies deciding to use CM Opportunities for generic manufacturers – cost savings, beyond production efficiencies Moderator: Wayne Weiner, Principal, Pharmatech Solutions LLC Panellists: Bikash Chatterjee, CEO, Pharmatech Associates- A USP Company Graziano Castaldi, President/CEO, Chemelectiva Kai Donsbach, Professor, Virginia Commonwealth University William A. Hein II, Senior Director Technical Operations Small Molecule Platform, Janssen
    • Webinar Form and fit: Mobilizing integrated resources to transform complex small molecules into high-performing drugs

      As clients seek to gain maximum benefit from each clinical stage, the advantages offered by contract partners with integrated services are making these higher returns tangible. This presentation will highlight key activities under Thermo Fisher’s integrated drug substance and product development services for the clinical development of small molecule APIs that decrease development risk, decrease timelines, and enable success in Phase 1 and beyond. This session was broadcast as part of the CPHI North America show.
    • Webinar Novel Excipient Pilot Program Review

      In this webinar, originally broadcast as a part of Pharmapack Europe 2022, speaker Nigel Langley, Director Technical Service & Scientific Affairs, BASF Pharma Solutions reviews the 'Novel Excipient Review Pilot Program'. Launched at the end of 2021, the voluntary Novel Excipient Review Pilot Program (Pilot Program) allows excipient manufacturers to obtain an FDA review of certain novel excipients before their use in drug formulations. Fundamental to the creation of the program, IPEC Americas talks us through the historical challenges that led to this first-in-kind program and an update from the FDA on the first four excipients approved in the pilot and what this means for the future of excipient manufacturing.
    • Webinar Covid Therapeutics Outlook

      Focus on Medicines for All's work in process improvements for COVID therapeutics, including work done thus far on remdesivir and molnupiravir. The session will also describe how Medicines for All shares its results with the global market and how this has led to uptake of its processes on critical COVID drugs. The Medicines for All Institute (M4ALL) is part of Virginia Commonwealth University; M4ALL is committed to improving access to high-quality medications across the globe by driving down production costs. M4ALL does this by optimizing active pharmaceutical ingredient (API) production and providing access to manufacturers around the world to enhance the security of medicine supply chains. This session was broadcast as part of the CPHI North America show.
    • Webinar Optimized Approach to Drug Development

      Take months off the development timelines of your large and small molecule discoveries. With Thermo Fisher Scientific's Quick to Care™ program, you can combine your drug substance and drug product development, demand planning and clinical trial supply execution into a single customized solution to simplify your supply chain and accelerate your discovery through clinical development. This session was broadcast as part of the CPHI North America show.
    • Webinar mRNA vaccines, Trends, Technologies and Supply Chain

      Over the past decade, outbreaks of H1N1 influenza, Sars-Cov, Ebola, and MERS have sparked ongoing conversations about strategic approaches and responses to pandemics and epidemics. With the spread of SARS-CoV-2 intensifying, scientists, together with pharmaceutical companies, are reinventing how to bring these life-saving drugs to market faster without impacting product quality, safety, or efficacy. The response has its own set of complex challenges that traditional manufacturing methods won’t solve. This webinar will tackle some of the key lessons learned from the COVID 19 situation, the role, application, and potential of mRNA Vaccines technologies, as well as some of the challenges and considerations for achieving a robust global vaccine supply chain.
    • Webinar CPHI Webinar Series Parenteral Drug Market: Meeting Escalating Challenges

      The percentage of parenteral drugs approved continues to increase as the overall drug market expands and new therapies for chronic and rare diseases enter the pipeline. In addition to this, swift advancement in biosimilars and biological products is projected to drive the parenteral drugs market growth in the years ahead. Manufacturers face increasing complexity, not just because of the drug substances but also due to formulations, patient-centric delivery technologies, and regulatory requirements, which are all further complicated by abbreviated development timelines. This session will aim to look at trends and challenges in today’s parenteral manufacturing and development market. Discussion will cover: Discuss key trends in the parenteral dosage development and manufacturing market Overcome complex formulation challenges: solubility, stability, process Navigate a complex regulatory environment (IND, filing, etc.) Build success in early development to enable commercial success Shorten timelines to get to market quicker Bolstering Capabilities for Parenteral Drug Development & Build a robust process development program Why attend? Parenteral Drugs: Recent Approvals and Growth Dynamics Key Trends and Issues Impacting Parenteral Development and Manufacturing Overcoming challenges getting drugs to market. WATCH FOR FREE